Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D

Nephrology Dialysis Transplantation

Volumn 27, Issue 9, 2012, Pages 3523-3531

  Marckmann, Peter ^a,b   Agerskov, Hanne ^a   Thineshkumar, Sasikala ^b   Bladbjerg, Else Marie ^c   Sidelmann, Johannes J ^c   Jespersen, Jorgen ^c   Nybo, Mads ^a   Rasmussen, Lars M ^a   Hansen, Ditte ^d   Scholze, Alexandra ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d ROSKILDE HOSPITAL   (Denmark)

Author keywords

cholecalciferol; chronic kidney disease; FGF 23; pleiotropic effects; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; C REACTIVE PROTEIN; CALCIUM; CINACALCET; COLECALCIFEROL; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR 23; INTERLEUKIN 6; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BONE MINERAL; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VISUAL ANALOG SCALE; VITAMIN DEFICIENCY;

AGED; BIOLOGICAL MARKERS; CALCIFICATION, PHYSIOLOGIC; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; MUSCLES; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84865752230     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs138     Document Type: Article

References (47)

1. Gonzalez EA, Sachdeva A, Oliver DA et al. Vitamin D insufficiency and deficiency in chronic kidney disease. Am J Nephrol 2004; 24: 503-510.
2. Ravani P, Malberti F, Tripepi G et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2008; 75: 88-95.
3. Ewers B, Gasbjerg A, Moelgaard C et al. Vitamin D status in kidney transplant patients: need for intensified routine supplementation. Am J Clin Nutr 2008; 87: 431-437.
4. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010; 21: 1427-1435.
5. Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impaires vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int 2011; 79: 715-729.
6. Cunningham J, Zehnder D. New vitamin D analogs and changing therapeutic paradigms. Kidney Int 2011; 79: 702-707.
7. Dusso A, Lopez-Hilker S, Rapp N et al. Extra-renal production of calcitriol in chronic renal failure. Kidney Int 1988; 34: 368-375.
8. Zehnder D, Bland R, Williams MC et al. Extrarenal expression of 25-hydroxyvitamin D3-1α hydroxylase. J Clin Endocrinol Metab 2001; 86: 888-894.
9. Dusso AS, Brown AJ, Slatopolski E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28.
10. Cantorna MT, Zhu Y, Froicu M et al. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004; 80 (Suppl): 1717S-1720S.
11. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
12. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 2008; 87 (Suppl): 1080S-1086S.
13. Bouillon R, Carmeliet G, Verlinden L et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726-776.
14. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620.
15. Shroff R, Knott C, Rees L. The virtues of vitamin D-but how much is too much?. Pediatr Nephrol 2010; 25: 1607-1620.
16. Kidney disease: Improving global outcomes (KDIGO) CKD-MBD work group. KDIGO clinical guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney diseasemineral and bone disorder (CKD-MBD). Kidney Int 2009; 113: S1-S130.
17. Vasan RS. Biomarkers of cardiovascular disease. Molecular basis and practical considerations. Circulation 2006; 113: 2335-2362.
18. Thorsen H, Hansen TM, McKenna SP et al. Adaptation into Danish of the Stanford Health Assessment Questionnaire (HAQ) and the Rheumatoid Arthritis Quality of Life Scale (RAQoL). Scand J Rheumatol 2001; 30: 103-109.
19. Frimodt-Mler M, Nielsen AH, Kamper AL et al. Reproducibility of pulse-wave analysis and pulse-wave velocity determination in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 594-600.
20. Shah N, Bernardini J, Piraino B. Prevalence and correction of 25 (OH) vitamin D deficiency in peritoneal dialysis patients. Perit Dial Int 2005; 25: 362-366.
21. DeVille J, Thorp M, Tobin L et al. Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease. Nephrology 2006; 11: 555-559.
22. Zisman AL, Hristova M, Ho LT et al. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007; 27: 36-43.
23. Saab G, Young DO, Gincherman Y et al. Prevalence of vitamin D deficiency and safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105: c132-c138.
24. Al-Aly Z, Qazi RA, Gonzez EA et al. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007; 50: 59-68.
25. Jean G, Souberbielle J, Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 2009; 24: 3799-3805.
26. Tokmak F, Quack I, Schieren G et al. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 2008; 23: 4016-4020.
27. Jean G, Terrat JC, Vanel T et al. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 month of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 2008; 110: c58-c65.
28. Dogan E, Erkoc R, Sayarlioglu H et al. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney disease patients. Ren Fail 2008; 30: 407-410.
29. Okša A, SpustovV, KrivošikovZ et al. Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease. Kidney Blood Press Res 2008; 31: 322-329.
30. Rucker D, Tonelli M, Coles MG et al. Vitamin D insufficiency and treatment with oral vitamin D3 in northern-dwelling patients with chronic kidney disease. J Nephrol 2009; 22: 75-82.
31. Stubbs JR, Idiculla A, Slusser J et al. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010; 21: 353-361.
32. Matias PJ, Jorge C, Ferreira C et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010; 5: 905-911.
33. Chandra P, Binongo JNG, Ziegler TR et al. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 2008; 14: 10-17.
34. Kooienga L, Fried L, Scragg R et al. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. Am J Kidney Dis 2009; 53: 408-416.
35. Gal-Moscovici A, Sprague SM. Use of vitamin D in chronic kidney disease patients. Kidney Int 2010; 78: 146-151.
36. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease. Am J Kidney Dis 2003; 42 (Suppl): S1-S201.
37. Michaud J, Naud J, Ouimet D et al. Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol 2010; 21: 1488-1497.
38. Wolf M. Fibroblast growth factor 23 and the future of phosphorus management. Curr Opin Nephrol Hypertens 2009; 18: 463-468.
39. Gutirez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
40. Isakova T, Xie H. Wei Y for the Chronic Renal Insufficiency Cohort (CRIC) Study group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439.
41. Mizobuchi M, Nakamura H, Tokumoto M et al. Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol 2010; 121: 188-192.
42. Hofman-Bang J, Martuseviciene G, Santini MA et al. Increased parathyroid expression of klotho in uremic rats. Kidney Int 2010; 78: 1119-1127.
43. Wu-Wong JR, Nakane M, Ma J et al. Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells. Am J Physiol Renal Physiol 2007; 293: F1592-F1604.
44. Vieth R. Vitamin D supplementation, 25-hydroxyvitanmin D concentrations, and safety. Am J Clin Nutr 1999; 69: 842-856.
45. Heaney RP. Vitamin D and calcium interactions: functional outcomes. Am J Clin Nutr 2008; 88: 541S-544S.
46. Aloia JF, Patel M, Dimaano R et al. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr 2008; 87: 1952-1958.
47. Binkley N, Krueger D. Evaluation and correction of low vitamin D status. Curr Osteoporos Rep 2008; 6: 95-99.